After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management platform, underpinned by digital technologies.
Digital health company Health2Sync will work with Sanofi on digitising its range of insulin products in Japan, extending an earlier alliance in other markets.
Arkansas has become the latest US state to issue a legal challenge to the big three insulin producers – Eli Lilly, Sanofi and Novo Nordisk – accusing them of deceptively driving up the pric
For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying to change that.
The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products.